Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celoxone is a brand of cefalexin (cephalexin), a first-generation cephalosporin antibiotic marketed by Nutramedica. It is a small molecule that exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. Specifically, it binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall, which prevents the cross-linking of peptidoglycan chains. This disruption leads to cell lysis and death. Celoxone is indicated for the treatment of various bacterial infections, including upper respiratory tract infections, skin and soft tissue infections, and pediatric infections caused by susceptible gram-positive bacteria such as *Staphylococcus* and *Streptococcus* species. It is available in oral formulations including capsules for adults and suspensions or drops for pediatric use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Celoxone.